IP Library Granted Patent US 9,062,288
Granted Patent B2
US 9,062,288 · App. 13/059,646 · Granted Jun 23, 2015

Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes

Inventor: Graham Vesey (Gordon, AU)
Assignee: Regeneus LTD
C12N5/0653A61K35/12A61K35/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,062,288
App. No.
13/059,646
Granted
Jun 23, 2015
Kind
B2
Abstract

Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent.

Claims (7)

1. A method for treating an inflammatory disorder or a cartilage disorder or alleviating pain associated with an inflammatory disorder in a subject, comprising the step of administering to the subject a pharmaceutical composition comprising a cell free extract prepared from an adipose tissue-derived cell suspension comprising adipocytes and adipose-derived non-adipocyte cells.

2. The method according to claim 1 , wherein the adipose tissue-derived cell suspension is freshly isolated.

3. The method according to claim 1 , wherein the adipose tissue-derived cell suspension is autologous to the subject.

4. The method use according to claim 1 , wherein the adipose tissue-derived cell suspension is allogeneic to the subject.

5. The method according to claim 1 , wherein the subject is a human.

6. The method according to claim 1 , wherein the pharmaceutical composition is a veterinary composition and the subject is a non-human mammal.

7. The method according to claim 1 , wherein the inflammatory disorder is selected from a joint-related inflammatory disorder, corneal inflammation, or skin inflammation.

Assignments (2)
CHANGE OF NAME Recorded Aug 13, 2013
From: REGENEUS PTY LTD
To: REGENEUS LTD
Reel/Frame 031012/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2011
From: VESEY, GRAHMAN
To: REGENEUS PTY LTD.
Reel/Frame 026659/0475 →
Priority Claims (2)
AU 2008904326 · Aug 22, 2008 · national
AU 2009201915 · May 14, 2009 · national
Continuity (1)
Related Publication 20110293577A1 · Dec 1, 2011